Suxia Luo
Zhengzhou University · 127 works · 6,706 citations · h-index 32
Top works
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
- Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4
- Regulation of PD-L1 expression in the tumor microenvironment
- Efficacy and safety of a novel anti‐HER2 therapeutic antibody RC48 in patients with HER2‐overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single‐arm phase II study
- Epidemiological trends of women’s cancers from 1990 to 2019 at the global, regional, and national levels: a population-based study
- LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study
- Prospects for combining immune checkpoint blockade with PARP inhibition
- The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1
- Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.
- The role of cancer-derived microRNAs in cancer immune escape
- Pembrolizumab in HER2-Positive Gastric Cancer
- Prognostic evaluation of Nanog, Oct4, Sox2, PCNA, Ki67 and E-cadherin expression in gastric cancer
- Advances and perspectives of PARP inhibitors
- Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma
- The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction
- Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
- Investigation on nutrition status and clinical outcome of patients with common cancers in Chinese patients: a multicenter prospective study protocol
- Global burden and trend of acute lymphoblastic leukemia from 1990 to 2017
- Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial
- A phase II study of efficacy and safety of RC48-ADC in patients with locally advanced or metastatic HER2-overexpressing gastric or gastroesophageal junction cancers.